文献速递肾血管病与高血压急性肾损伤

自体间充质干细胞改善肾血管病皮质灌注

Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease.
PubMed 文献 · J Am Soc Nephrol · 2017-05-01

这项首次人体剂量递增研究评估了经动脉输注自体脂肪来源间充质干细胞(MSC)联合标准化药物治疗对动脉粥样硬化性肾血管病(RVD)患者的安全性和疗效。干预组(n=14)接受单次MSC输注(1.0×10^5或2.5×10^5 cells/kg),对照组(n=14)仅接受标准化药物治疗。三个月后,MSC组狭窄后肾脏皮质灌注和肾血流量增加,肾组织缺氧改善,单肾GFR保持稳定,而对照组单肾GFR下降,MSC输注耐受良好。

要点

  • 经动脉自体MSC输注在RVD患者中耐受良好。
  • MSC输注后狭窄后肾脏皮质灌注和肾血流量增加,肾组织缺氧改善。
  • MSC组单肾GFR稳定,对照组下降,组间差异显著。

核心结论

  • 经动脉输注自体脂肪来源MSC在RVD患者中安全,且与肾脏组织氧合和皮质血流量增加相关,单肾GFR保持稳定。

研究设计与样本

  • 首次人体剂量递增研究,干预组(n=14)接受单次MSC输注(1.0×10^5或2.5×10^5 cells/kg,各n=7)联合标准化药物治疗,对照组(n=14)仅接受标准化药物治疗,按年龄、肾功能和狭窄严重程度匹配。

主要发现

  • MSC输注耐受良好。
  • 三个月后,狭窄后肾脏皮质灌注和肾血流量从151.8升至185.5 ml/min(P=0.01)。
  • 对侧肾脏肾血流量从212.7升至271.8 ml/min(P=0.01)。
  • 狭窄后肾脏缺氧(R2*>30/s占全肾百分比)从12.1%(IQR 3.3%-17.8%)降至6.8%(IQR 1.8%-12.9%),P=0.04。
  • 单肾GFR在MSC组保持稳定,对照组下降(-3% vs -24%,P=0.04)。

临床怎么用

  • 对于无血运重建指征的RVD患者,经动脉自体MSC输注可能作为辅助治疗改善肾脏灌注和氧合,但需进一步研究确认。

局限性

  • 样本量小(每组n=14),为首次人体剂量递增研究,需更大规模研究验证疗效和长期安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Atherosclerotic renovascular disease (RVD) reduces renal blood flow (RBF) and GFR and accelerates poststenotic kidney (STK) tissue injury. Preclinical studies indicate that mesenchymal stem cells (MSCs) can stimulate angiogenesis and modify immune function in experimental RVD. We assessed the safety and efficacy of adding intra-arterial autologous adipose-derived MSCs into STK to standardized medical treatment in human subjects without revascularization. The intervention group (n=14) received a single infusion of MSC (1.0 × 105 or 2.5 × 105 cells/kg; n=7 each) plus standardized medical treatment; the medical treatment only group (n=14) included subjects matched for age, kidney function, and stenosis severity. We measured cortical and medullary volumes, perfusion, and RBF using multidetector computed tomography. We assessed tissue oxygenation by blood oxygen level-dependent MRI and GFR by iothalamate clearance. MSC infusions were well tolerated. Three months after infusion, cortical perfusion and RBF rose in the STK (151.8-185.5 ml/min, P=0.01); contralateral kidney RBF increased (212.7-271.8 ml/min, P=0.01); and STK renal hypoxia (percentage of the whole kidney with R2*>30/s) decreased (12.1% [interquartile range, 3.3%-17.8%] to 6.8% [interquartile range, 1.8%-12.9%], P=0.04). No changes in RBF occurred in medical treatment only subjects. Single-kidney GFR remained stable after MSC but fell in the medical treatment only group (-3% versus -24%, P=0.04). This first-in-man dose-escalation study provides evidence of safety of intra-arterial infusion of autologous MSCs in patients with RVD. MSC infusion without main renal artery revascularization associated with increased renal tissue oxygenation and cortical blood flow.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Saad A, Dietz AB, Herrmann SMS, et al. Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease. J Am Soc Nephrol. 2017. PMID: 28461553. doi:10.1681/ASN.2017020151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。